4DMT Highlights Recent Clinical Pipeline Progress, Near-Term Milestones and Organizational Updates
January 04, 2024 08:00 ET
|
4D Molecular Therapeutics, Inc.
Poised for multiple meaningful catalysts in 2024 driven by strong clinical progress across large market programs in wet age-related macular degeneration (wet AMD), diabetic macular edema (DME) and...
Claris Bio Emerges From Stealth With a New Investor and Prepares for Next Development Stage With Late-Stage Data Expected in 1H24
January 04, 2024 08:00 ET
|
Claris Biotherapeutics, Inc.
Claris Bio emerges from stealth with $57 million in funding as it prepares for 1H2024 readout of late-stage study in neurotrophic keratopathy
Ocuphire Pharma Receives FDA Agreement Under Special Protocol Assessment for LYNX-2 Phase 3 Trial of Phentolamine Ophthalmic Solution for the Treatment of Decreased Visual Acuity under Dim (mesopic) Light Conditions
January 04, 2024 08:00 ET
|
Ocuphire Pharma
FARMINGTON HILLS, Mich., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing...
Active Pharmaceutical Ingredients Market Size Worth USD 329.80 Billion in 2032 | Emergen Research
January 04, 2024 07:48 ET
|
Emergen Research
Vancouver, Jan. 04, 2024 (GLOBE NEWSWIRE) -- The global Active Pharmaceutical Ingredients (API) market, valued at USD 144.70 Billion in 2022, is poised to experience a rapid revenue Compound Annual...
Krystal Biotech Receives Permanent J-code (J3401) for VYJUVEK®
January 04, 2024 07:00 ET
|
Krystal Biotech, Inc.
PITTSBURGH, Jan. 04, 2024 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company focused on the discovery, development and...
Use of SGLT2 Inhibitors Continues to Expand for the Treatment of Chronic Kidney Disease, with Eli Lilly/Boehringer Ingelheim’s Jardiance Making Significant Strides Following Label Expansion
January 03, 2024 16:13 ET
|
Spherix Global Insights
EXTON, PA, Jan. 03, 2024 (GLOBE NEWSWIRE) -- Since 2019, audited records of chronic kidney disease (CKD) non-dialysis patients has revealed an ongoing, annual uptick in the proportion of...
US Neurologists Optimistic Regarding the Huntington’s Disease Treatment Pipeline, Emphasizing Halting Neurodegeneration as Leading Treatment Priority
January 03, 2024 09:46 ET
|
Spherix Global Insights
EXTON, PA, Jan. 03, 2024 (GLOBE NEWSWIRE) -- Huntington’s disease (HD) could be called the perfect storm of neurodegenerative diseases. It causes a loss of critical striatal neurons which affect not...
4DMT and Arbor Biotechnologies Establish Partnership to Co-Develop and Co-Commercialize Next-Generation Genetic Medicines for CNS Diseases
January 03, 2024 08:01 ET
|
Arbor Biotechnologies Inc
Partnership brings together two leaders in next-generation genetic medicines to engineer, co-develop and co-commercialize (50:50 profit share) AAV-delivered CRISPR/Cas-based therapeutics for up to six...
4DMT and Arbor Biotechnologies Establish Partnership to Co-Develop and Co-Commercialize Next-Generation Genetic Medicines for CNS Diseases
January 03, 2024 08:00 ET
|
4D Molecular Therapeutics, Inc.
Partnership brings together two leaders in next-generation genetic medicines to engineer, co-develop and co-commercialize (50:50 profit share) AAV-delivered CRISPR/Cas-based therapeutics for up to six...
ABVC BioPharma and its Subsidiary Receive $460M From AiBtl BioPharma as the First Milestone Payment of Global Licensing Fees
January 03, 2024 07:24 ET
|
ABVC BioPharma, Inc.
FREMONT, CA , Jan. 03, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC BioPharma, Inc. (NASDAQ: ABVC) and its subsidiary BioLite, Inc. ("Company"), a clinical-stage biopharmaceutical company...